30:43

Aernout van Haarst Presents Optimizing Early Clinical Trials in Special Populations

1:00:13

Bioanalytical Support of Biosimilars Expect the Unexpected

54:18

Clinical and Bioanalytical Aspects of Immune Monitoring via ELISpot

56:22

Nitrosamine Impurities in Rifampin – What Does it Mean for Your Drug Drug Interaction DDI Study

58:30

AAV Vector Shedding Assay—Best Practices in Clinical Gene Therapy Method Development

57:35

Drug Labeling Studies in Clinical Pharmacology: Recent FDA/EMA Updates

1:00:47

Optimizing PBMC and Flow Cytometry Results Webinar

47:37

Onsite Pharmacy Compounding for Your Phase 1 Clinical Study